Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2HD1

Crystal structure of PDE9 in complex with IBMX

Replaces:  1TBM
Summary for 2HD1
Entry DOI10.2210/pdb2hd1/pdb
Related1TBM
DescriptorPhosphodiesterase 9A, ZINC ION, MAGNESIUM ION, ... (5 entities in total)
Functional Keywordscgmp, pde9, ibmx, hydrolase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight77717.06
Authors
Huai, Q.,Wang, H.,Zhang, W.,Colman, R.W.,Robinson, H.,Ke, H. (deposition date: 2006-06-19, release date: 2006-06-27, Last modification date: 2024-04-03)
Primary citationHuai, Q.,Wang, H.,Zhang, W.,Colman, R.W.,Robinson, H.,Ke, H.
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor IBMX binding
Proc.Natl.Acad.Sci.USA, 101:9624-9629, 2004
Cited by
PubMed Abstract: Cyclic nucleotide phosphodiesterases (PDEs) are enzymes controlling cellular concentrations of the second messengers cAMP and cGMP. The crystal structure of the catalytic domain of PDE9A2, a member of a PDE family specifically hydrolyzing cGMP, has been determined at 2.23-A resolution. The PDE9A2 catalytic domain closely resembles the cAMP-specific PDE4D2 but is significantly different from the cGMP-specific PDE5A1, implying that each individual PDE family has its own characteristic substrate recognition mechanism. The different conformations of the H and M loops between PDE9A2 and PDE5A1 imply their less critical roles in nucleotide recognition. The nonselective inhibitor 3-isobutyl-1-methylxanthine (IBMX) binds to a similar subpocket in the active sites of PDE4, PDE5, and PDE9 and has a common pattern of the binding. However, significantly different orientations and interactions of IBMXs are observed among the three PDE families and also between two monomers of the PDE9A2 dimer. The kinetic properties of the PDE9A2 catalytic domain similar to those of full-length PDE9A imply that the N-terminal regulatory domain does not significantly alter the catalytic activity and the IBMX inhibition.
PubMed: 15210993
DOI: 10.1073/pnas.0401120101
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.23 Å)
Structure validation

236371

PDB entries from 2025-05-21

PDB statisticsPDBj update infoContact PDBjnumon